Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide
Authors' conclusion
In SURMOUNT-1, tirzepatide-associated improvements in cardiometabolic risk factors positively related to the degree of weight reduction, but the pattern varied depending on outcome measure.
Study context
- Population
- Adults with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide; mean age 45.4 years, mean BMI 37.9 kg/m², 68% female
- Participants
- 1,605 adults
- Comparison
- Cardiometabolic risk factor changes by degree of weight reduction with tirzepatide
- Primary endpoint
- Changes in cardiometabolic risk factors by weight reduction
- Follow-up
- Baseline to week 72
Methodological detailspost hoc, phase 3, double-blind, 119 sites in 9 countries
- Post hoc
- Phase 3
- Double-blind
- 119 sites in 9 countries
Primary result
As reported in the abstract
Cardiometabolic risk factor changes in participants losing ≥35% body weight
- Systolic BP mean change
- −14.2 mm Hg (95% CI −16.1 to −12.3 mm Hg)
- Diastolic BP mean change
- −9.2 mm Hg (CI −10.6 to −7.8 mm Hg)
- Waist circumference mean change
- −32.4 cm (CI −33.5 to −31.3 cm)
- Homeostatic model assessment of insulin resistance (HOMA-IR) mean change
- −59.7% (CI −63.6% to −55.3%)
- HbA1c mean change
- −0.65 percentage point (CI −0.70 to −0.61 percentage point)
Original publication
Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide. Ann Intern Med. Published 24 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →